Delisting risk
ClearOne (CLRO)
Supports legacy warranties while pursuing a merger with neurostimulation developer Cortigent.
$5.10
At close−0.12 (−2.30%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 4 | 4 | 2 | 3 | 3 | 2 | 2 | 0 | 0 | 0 | 0 |
| Cost of revenue | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Gross profit | 2 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 1 | 1 | 1 | 1 | |
| Research & development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 0 |
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 1 | 1 | 1 | 1 | |
| Selling & marketing | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| General & administrative | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −2 | 0 | 0 |
| Operating income | −1 | −2 | −2 | −3 | −2 | −2 | −3 | −5 | −1 | −1 | −1 | −1 |
| 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | −5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −1 | 3 | −2 | −3 | −2 | −2 | −3 | −5 | −1 | −1 | −1 | −1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −1 | 3 | −2 | −3 | −2 | −2 | −3 | −5 | −1 | −1 | −1 | −1 |
| Discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −13 | −4 | 0 | 0 |
| Net income | −1 | 3 | −2 | −3 | −2 | −2 | −3 | −5 | −14 | −5 | 0 | −1 |
| EPS, basic | −$0.06 | $0.11 | −$0.08 | −$0.12 | −$0.09 | −$0.09 | −$0.11 | −$2.64 | −$7.92 | −$2.38 | −$0.20 | −$0.34 |
| EPS, diluted | −$0.06 | $0.11 | −$0.08 | −$0.12 | −$0.09 | −$0.09 | −$0.11 | −$0.33 | −$1.00 | −$0.36 | −$0.20 | −$0.34 |
| Weighted average shares, basic | 24 | 24 | 24 | 24 | 24 | 24 | 25 | 2 | 2 | 2 | 2 | 3 |
| Weighted average shares, diluted | 24 | 24 | 24 | 24 | 24 | 24 | 25 | 14 | 14 | 14 | 3 | 3 |
| EBITDA | −1 | 3 | −2 | −3 | −2 | −2 | −3 | −4 | −1 | −1 | −1 | −1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | 3 | −2 | −3 | −2 | −2 | −3 | −5 | −1 | −1 | −1 | −1 |